Quince Therapeutics Inc
NASDAQ:QNCX

Watchlist Manager
Quince Therapeutics Inc Logo
Quince Therapeutics Inc
NASDAQ:QNCX
Watchlist
Price: 2.01 USD 1.52%
Market Cap: 87m USD
Have any thoughts about
Quince Therapeutics Inc?
Write Note

Intrinsic Value

QNCX's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one QNCX stock under the Base Case scenario is 1.43 USD. Compared to the current market price of 2.01 USD, Quince Therapeutics Inc is Overvalued by 29%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

QNCX Intrinsic Value
1.43 USD
Overvaluation 29%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Quince Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for QNCX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about QNCX?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Quince Therapeutics Inc

Provide an overview of the primary business activities
of Quince Therapeutics Inc.

What unique competitive advantages
does Quince Therapeutics Inc hold over its rivals?

What risks and challenges
does Quince Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Quince Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Quince Therapeutics Inc.

Provide P/S
for Quince Therapeutics Inc.

Provide P/E
for Quince Therapeutics Inc.

Provide P/OCF
for Quince Therapeutics Inc.

Provide P/FCFE
for Quince Therapeutics Inc.

Provide P/B
for Quince Therapeutics Inc.

Provide EV/S
for Quince Therapeutics Inc.

Provide EV/GP
for Quince Therapeutics Inc.

Provide EV/EBITDA
for Quince Therapeutics Inc.

Provide EV/EBIT
for Quince Therapeutics Inc.

Provide EV/OCF
for Quince Therapeutics Inc.

Provide EV/FCFF
for Quince Therapeutics Inc.

Provide EV/IC
for Quince Therapeutics Inc.

Show me price targets
for Quince Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Quince Therapeutics Inc?

How accurate were the past Revenue estimates
for Quince Therapeutics Inc?

What are the Net Income projections
for Quince Therapeutics Inc?

How accurate were the past Net Income estimates
for Quince Therapeutics Inc?

What are the EPS projections
for Quince Therapeutics Inc?

How accurate were the past EPS estimates
for Quince Therapeutics Inc?

What are the EBIT projections
for Quince Therapeutics Inc?

How accurate were the past EBIT estimates
for Quince Therapeutics Inc?

Compare the revenue forecasts
for Quince Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Quince Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Quince Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Quince Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Quince Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Quince Therapeutics Inc with its peers.

Analyze the financial leverage
of Quince Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Quince Therapeutics Inc.

Provide ROE
for Quince Therapeutics Inc.

Provide ROA
for Quince Therapeutics Inc.

Provide ROIC
for Quince Therapeutics Inc.

Provide ROCE
for Quince Therapeutics Inc.

Provide Gross Margin
for Quince Therapeutics Inc.

Provide Operating Margin
for Quince Therapeutics Inc.

Provide Net Margin
for Quince Therapeutics Inc.

Provide FCF Margin
for Quince Therapeutics Inc.

Show all solvency ratios
for Quince Therapeutics Inc.

Provide D/E Ratio
for Quince Therapeutics Inc.

Provide D/A Ratio
for Quince Therapeutics Inc.

Provide Interest Coverage Ratio
for Quince Therapeutics Inc.

Provide Altman Z-Score Ratio
for Quince Therapeutics Inc.

Provide Quick Ratio
for Quince Therapeutics Inc.

Provide Current Ratio
for Quince Therapeutics Inc.

Provide Cash Ratio
for Quince Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Quince Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Quince Therapeutics Inc?

What is the current Free Cash Flow
of Quince Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Quince Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Quince Therapeutics Inc

Current Assets 51.7m
Cash & Short-Term Investments 47.8m
Other Current Assets 3.9m
Non-Current Assets 74.8m
Long-Term Investments 78k
PP&E 767k
Intangibles 64.5m
Other Non-Current Assets 9.4m
Current Liabilities 5.4m
Accounts Payable 1.6m
Accrued Liabilities 3.8m
Non-Current Liabilities 76.2m
Long-Term Debt 14.9m
Other Non-Current Liabilities 61.3m
Efficiency

Earnings Waterfall
Quince Therapeutics Inc

Revenue
0 USD
Operating Expenses
-38.1m USD
Operating Income
-38.1m USD
Other Expenses
-15.2m USD
Net Income
-53.3m USD

Free Cash Flow Analysis
Quince Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

QNCX Profitability Score
Profitability Due Diligence

Quince Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

Quince Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

QNCX Solvency Score
Solvency Due Diligence

Quince Therapeutics Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
58/100
Solvency
Score

Quince Therapeutics Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

QNCX Price Targets Summary
Quince Therapeutics Inc

Wall Street analysts forecast QNCX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for QNCX is 9.18 USD with a low forecast of 6.06 USD and a high forecast of 12.6 USD.

Lowest
Price Target
6.06 USD
201% Upside
Average
Price Target
9.18 USD
357% Upside
Highest
Price Target
12.6 USD
527% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for QNCX?

Click here to dive deeper.

Dividends

Quince Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for QNCX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

QNCX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Quince Therapeutics Inc Logo
Quince Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

85.7m USD

Dividend Yield

0%

Description

Cortexyme, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. The company is headquartered in South San Francisco, California and currently employs 55 full-time employees. The company went IPO on 2019-05-09. The firm is focused on advancing precision therapeutics targeting debilitating and rare diseases. The firm has discovered a bone-targeting drug platform capable of delivering small molecules, peptides, or large molecules directly to the site of broad bone fractures and disease designed to promote more healing with fewer off-target safety concerns. The Company’s lead compound, NOV004, is an anabolic peptide engineered to target and concentrate at the bone fracture site. Its discovery pipeline is focused on expanding across multiple skeletal therapeutic indications, including osteogenesis imperfecta, fractures, spinal fusion, and other severe diseases of bone such as cancer or infection. The firm's pipeline also includes legacy neuroscience and antiviral programs available for out-licensing, which include COR588, COR388, COR852 and COR803.

Contact

CALIFORNIA
South San Francisco
269 East Grand Ave
+14159105717
quincetx.com

IPO

2019-05-09

Employees

55

Officers

CEO, Chief Medical Officer & Director
Dr. Dirk Thye M.D.
President
Dr. Charles S. Ryan J.D., Ph.D.
Chief Business Officer, COO, Chief Compliance Officer and Principal Financial & Accounting Officer
Mr. Brendan Hannah M.B.A.
Chief Technology Officer
Mr. Giovanni Mambrini M.Sc.
Chief Scientific Officer
Dr. Guenter R. Janhofer M.D., Ph.D.
Vice President of Corporate Communications & Investor Relations
Ms. Stacy Roughan
Show More
Vice President of Human Resources
Ms. Mary Ellen Sillivos
Head of Discovery
Dr. Stewart A. Low Ph.D.
Chief Commercial Officer
Mr. Thomas Sabia M.B.A.
Head of Regulatory Affairs
Ms. Pamela M. Williamson FRAPS, M.B.A., RAC
Show Less

See Also

Discover More
What is the Intrinsic Value of one QNCX stock?

The intrinsic value of one QNCX stock under the Base Case scenario is 1.43 USD.

Is QNCX stock undervalued or overvalued?

Compared to the current market price of 2.01 USD, Quince Therapeutics Inc is Overvalued by 29%.

Back to Top